Journal article
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS
N Stewart, S Simpson, I Van Der Mei, AL Ponsonby, L Blizzard, T Dwyer, F Pittas, D Eyles, P Ko, BV Taylor
Neurology | Published : 2012
Abstract
Objective: To determine whether interferon-β (IFN-β) medication use is associated with vitamin D evels and whether the two interact in exerting effects on relapse risk. Methods: In a prospective cohort of 178 persons with clinically definite multiple sclerosis (MS) iving in southern Tasmania in 2002-2005, serum 25-hydroxyvitamin D [25(OH)D] was measured biannually, with assessment by questionnaire for relevant factors, including IFN-β treatment. Results: Subjects reporting IFN-β use had significantly higher mean 25(OH)D than persons who did not (p < 0.001). This was mediated by an interaction between personal sun exposure and IFN-β, with treated persons realizing nearly three times 25(OH)D p..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
The MS Longitudinal Study was funded by a grant from the Australian National Health & Medical Research Council (Project 211308). Additional funding for 25(OH)D measures provided by the Trish Foundation. Additional funding for 1,25(OH)<INF>2</INF>D measures provided by a University of Tasmania Rising Star Award. I.v.d.M. is supported by a Future Fellowship from the Australian Research Council.